Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Arcutis Biotherapeutics, Inc. (ARQT)

16.52   -0.21 (-1.26%) 02-08 10:04
Open: 16.74 Pre. Close: 16.73
High: 16.74 Low: 16.52
Volume: 15,648 Market Cap: 1,007(M)

Technical analysis

as of: 2023-02-08 9:46:03 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 20.19     One year: 23.58
Support: Support1: 14.52    Support2: 12.81
Resistance: Resistance1: 17.29    Resistance2: 20.19
Pivot: 16.36
Moving Average: MA(5): 16.59     MA(20): 15.78
MA(100): 17.09     MA(250): 19.36
MACD: MACD(12,26): 0.3     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 81.6     %D(3): 81.4
RSI: RSI(14): 58.1
52-week: High: 27.39  Low: 12.81
Average Vol(K): 3-Month: 808 (K)  10-Days: 595 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ARQT ] has closed below upper band by 25.3%. Bollinger Bands are 63.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.91 - 16.99 16.99 - 17.06
Low: 16.17 - 16.26 16.26 - 16.35
Close: 16.59 - 16.73 16.73 - 16.86

Company Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Headline News

Wed, 08 Feb 2023
Arcutis to Report Fourth Quarter 2022 Financial Results and ... - GuruFocus.com

Tue, 07 Feb 2023
11208 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ... - MarketBeat

Sat, 04 Feb 2023
Arcutis Biotherapeutics, Inc. is acquired by Barclays PLC for 106,001 ... - Best Stocks

Fri, 03 Feb 2023
2023-02-03 | NDAQ:ARQT | Press Release | Arcutis Biotherapeutics ... - Stockhouse

Fri, 20 Jan 2023
Jennison Associates LLC Expands Its Investment in Arcutis ... - Best Stocks

Thu, 19 Jan 2023
Arcutis up 9% as Cowen says to add to positions as shares are ... - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 61 (M)
% Held by Insiders 4.651e+007 (%)
% Held by Institutions 3.2 (%)
Shares Short 9,970 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.0377e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -41
Return on Assets (ttm) 998.4
Return on Equity (ttm) -42.5
Qtrly Rev. Growth 725000
Gross Profit (p.s.) 0
Sales Per Share -204.32
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -238 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.3
Price to Book value 0
Price to Sales -0.09
Price to Cash Flow 1.8

Stock Dividends

Dividend 0
Forward Dividend 1.074e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.